A recent trial of the drug Tamoxifen with patients who were experiencing mania, or who were in a mixed state that included mania as a component, significantly reduced the symptoms of mania in nearly half the sample.
Tamoxifen is normally associated with the treatment of breast cancer but its action is to inhibit a group of enzymes known as protein kinase C. This has relevance to bipolar disorder as abnormal activity by these enzymes is know to affect judgments, problem-solving,...
Friday, Central Connecticut. I'm at my mom's place, not far from where I grew up. My brother and sister-in-law will be arriving shortly.... Read more »
A couple of months ago, in the course of replacing many of my articles on mcmanweb, I found myself writing this: I would emphasize that... Read more »
Two recent shareposts, “The Depression-Mania Two Step” (Part I and Part II ), zeroed in on a crucial fact that tends to be overlooked... Read more »
Do you know the difference between Bipolar I and Bipolar II Disorders? It's that people with Bipolar I experience mania, while those with... Read more »
Today I’ll address some more of the questions you’ve emailed me. As a reminder, I can only answer general questions, so I need to... Read more »
Bipolar sufferer Laurel Lemke moved in and out of hospitals before she was finally diagnosed with the condition. And though her bipolar disorder will... Read more »
Though going to college can be stressful for all young adults, experts say those who have bipolar disorder or who are at risk for the condition are... Read more »
Featuring Content From:
By using this service, you accept our Terms of Use. Please read them. The consumer health information on is for informational purposes only and is not a substitute for medical advice or treatment for any medical conditions. You should promptly seek professional medical care if you have any concern about your health, and you should always consult your physician before starting a fitness regimen. Copyright © 2012 Remedy Health Media, LLC. All Rights Reserved.
